| Identification | More | [Name]
Naphazoline nitrate | [CAS]
5144-52-5 | [Synonyms]
2-(1-NAPHTHYLMETHYL)-2-IMIDAZOLINE NITRATE
2-(1-NAPHTHYLMETHYL)IMIDAZOLINE NITRATE
2-[1-NAPHTHYLMETHYL]IMIDAZOLINE NITRATE SALT
2-(1-NAPHTHYLMETHYL)IMIDAZOLINIUM NITRATE
LABOTEST-BB LT00134653
NAPHAZOLINE NITRATE
NAPHAZOLINE NITRATE SALT
NAPHAZOLINI NITRAS
2-(1-naphthylmethyl)-2-imidazolinmononitrate
4,5-dihydro-2-(1-naphthalenylmethyl)-1h-imidazolmononitrate
naftizin
naphthisen
naphthizen
naphtyzin
privinenitrate
rinazin
naphazoline nitrate crystalline
NAPHAZOLINE NITRATE, PH EUR
NAPHAZOLINE NITRATE EXTRA PURE PH EUR
1H-Imidazole, 4,5-dihydro-2-(1-naphthalenylmethyl)-, mononitrate | [EINECS(EC#)]
225-915-4 | [Molecular Formula]
C14H15N3O3 | [MDL Number]
MFCD00014316 | [Molecular Weight]
273.29 | [MOL File]
5144-52-5.mol |
| Chemical Properties | Back Directory | [Appearance]
White or almost white, crystalline powder. | [Melting point ]
167-170 °C
| [solubility ]
Sparingly soluble in water, soluble in ethanol (96 per cent). | [form ]
neat | [color ]
White to off-white | [Sensitive ]
Hygroscopic | [BRN ]
3779329 | [InChIKey]
ZAHXYMFVNNUHCP-UHFFFAOYSA-N | [CAS DataBase Reference]
5144-52-5(CAS DataBase Reference) |
| Safety Data | Back Directory | [Hazard Codes ]
Xn | [Risk Statements ]
R22:Harmful if swallowed. | [Safety Statements ]
S22:Do not breathe dust .
S36/37:Wear suitable protective clothing and gloves . | [RIDADR ]
3249 | [WGK Germany ]
3
| [RTECS ]
NJ4376000
| [F ]
3-10 | [HazardClass ]
6.1(b) | [PackingGroup ]
III | [HS Code ]
29332900 |
| Hazard Information | Back Directory | [Chemical Properties]
White or almost white, crystalline powder. | [Uses]
antihistamine | [Definition]
ChEBI: Naphazoline nitrate is a member of naphthalenes. | [Indications]
Naphazoline hydrochloride and naphazoline nitrate are white or almost white crystalline powders soluble 1 in 6 and 1 in 36 water, respectively. These are potent sympathomimetic vasoconstrictors with a direct alpha-adrenergic receptor stimulatory action, and may be used as topical decongestants in 0.05% or 0.1% eyedrops. Frequent application of these solutions will produce a reactive hyperaemia. Instillation should not be repeated in less than 4-6 hours to avoid this rebound congestion.
Naphazoline eyedrops cause slight mydriasis and are contra-indicated in patients with actual or suspected closed-angle glaucoma.
Although not administered systemically, topical application of naphazoline has resulted in systemic absorption, and it is readily absorbed from the gastro-intestinal tract (Martindale, 1977). |
|
|